8-K: Tactile Medical Reports Strong Q1 2026 Results

Tactile Systems Technology, Inc. announced a 23% year-over-year revenue increase to $75.3 million in Q1 2026, alongside improved gross margin and a shift to positive Adjusted EBITDA.

Summary

• Total revenue for the first quarter of 2026 reached $75.3 million, a 23% increase compared to $61.3 million in the first quarter of 2025.
• Gross margin improved to 76.5% from 74% in the prior year's first quarter.
• The company reported a net loss of $1.8 million ($0.08 per diluted share) for Q1 2026, an improvement from a net loss of $3.0 million ($0.13 per diluted share) in Q1 2025.
• Adjusted EBITDA turned positive at $3.7 million, compared to an Adjusted EBITDA loss of $0.3 million in Q1 2025.
• The company repurchased $1.1 million of its stock during the quarter.
• FDA 510(k) clearance was received for the next-generation AffloVest airway clearance device.
• The 2026 full-year revenue outlook was updated to a range of $360 million to $368 million, representing 9% to 12% year-over-year growth.
• The full-year 2026 Adjusted EBITDA outlook remains in the range of $49 million to $51 million.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with significant year-over-year improvements in revenue, profitability, and key financial metrics, alongside positive strategic developments.

Positives

• Total revenue increased by 23% year-over-year to $75.3 million in Q1 2026.
• Gross margin expanded to 76.5% from 74% in Q1 2025.
• Net loss narrowed to $1.8 million from $3.0 million in the prior year's quarter.
• Adjusted EBITDA improved significantly from a loss of $0.3 million to a gain of $3.7 million.
• The company received FDA 510(k) clearance for its next-generation AffloVest device.
• The 2026 full-year revenue guidance was raised slightly to $360-$368 million.
• The acquisition of LymphaTech positions the company to support lymphedema patients across the full continuum of care.
• The company has $75.0 million in cash and no outstanding borrowings as of March 31, 2026.

Negatives

• The company reported a net loss of $1.8 million for the first quarter of 2026.
• Operating expenses increased by 19% to $59.1 million in Q1 2026 compared to $49.9 million in Q1 2025.

Risks

• The company's ability to obtain reimbursement from third-party payers for its products.
• Adverse economic conditions, including inflation, rising interest rates, or a recession.
• Adequacy of the company's liquidity to pursue its business objectives.
• Price increases for supplies and components, and wage and component price inflation.
• Loss of a key supplier or other supply chain disruptions.
• Entry of new competitors and/or competitive products.
• Compliance with and changes in federal, state, and local government laws and regulations.
• Technological obsolescence of, or quality issues with, the company's products.

Future Outlook

The company updated its 2026 financial outlook, now expecting full-year total revenue between $360 million and $368 million, representing 9% to 12% year-over-year growth. The outlook for full-year 2026 Adjusted EBITDA remains in the range of $49 million to $51 million.

Management Comments

• "We delivered a strong start to 2026, with first quarter revenue growth of 23% year-over-year driven by disciplined execution of our strategic priorities."
• "Performance in the quarter was broad-based and reflected the strength and durability of our go-to-market strategy, including increased productivity from a fully resourced sales organization, growing access to advanced therapy under the NCD, and continued momentum across both lymphedema and airway clearance."
• "Importantly, this top line strength translated into meaningful expansion in gross margin and adjusted EBITDA, underscoring the operating leverage in our model."
• "We also advanced our business transformation technology while demonstrating the operational agility required to respond effectively to an evolving regulatory environment."
• "Further, we have expanded our product portfolio and R&D capabilities through our acquisition of LymphaTech, positioning us to support lymphedema patients across the full continuum of care, beginning with accurate, timely, and objective diagnosis."
• "As we move through 2026 and beyond, we remain confident in the trajectory of our business and the multiple catalysts ahead, and we will continue to invest with intent and execute with discipline."

Industry Context

StockSavvy.ai notes that Tactile Medical's Q1 2026 results demonstrate continued growth in the medical technology sector, particularly in therapies for chronic disorders. The company's focus on expanding its product portfolio through acquisitions like LymphaTech and leveraging technology for operational efficiency aligns with broader industry trends towards integrated care solutions and diagnostic advancements.

Comparison to Industry Standards

• While specific comparable companies are not detailed in the filing, Tactile Medical's reported 23% year-over-year revenue growth in Q1 2026 is robust compared to many medical device companies that often experience single-digit or low double-digit growth rates.
• The improvement in gross margin to 76.5% suggests efficient cost management and strong pricing power, which are key indicators of operational strength within the medical device industry.
• The shift from an Adjusted EBITDA loss to a gain of $3.7 million indicates improving profitability and operational leverage, a positive sign when compared to industry peers facing margin pressures.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to improved financial performance and updated positive outlook. Share repurchase program also benefits shareholders.
• Patients: Continued access to and development of therapies for chronic disorders like lymphedema and chronic inflammatory lung disease.
• Employees: Continued investment in the business and operational agility may lead to stable employment and growth opportunities.
• Clinicians: Collaboration with clinicians to expand clinical evidence and raise awareness for at-home therapies.

Next Steps

• Continue to invest with intent and execute with discipline.
• Support lymphedema patients across the full continuum of care, beginning with accurate, timely, and objective diagnosis.
• Continue to expand product portfolio and R&D capabilities.
• Execute on strategic priorities to drive further growth and profitability.

Key Dates

Recommendation

The company demonstrated robust top-line growth, significant margin expansion, and a strong turnaround in profitability (Adjusted EBITDA). The raised revenue guidance and positive strategic developments, including FDA clearance and acquisition integration, suggest sustained momentum. This performance, coupled with a solid balance sheet and ongoing share repurchases, indicates a compelling investment opportunity.

Keywords

Tactile Systems Technology, TCMD, Medical Technology, Lymphedema, Airway Clearance, Financial Results, Q1 2026, 8-K Filing